Transcript Highlights:

• framework for stem cell and regenerative therapies derived from birth tissue, such as placental perinatal
• The population does not include common conditions like anxiety or depression.

Bills: SB1052, SB1115, SB1118, SB1120, SB1121, SB1124, SB1171, SB1172, SB1174, SB1175, SB1214, SB1233, SB1235, SB1316, SB1345, SB1372, SB1399, SB1458, SB1494, SB1496, SB1564, SB1602, SB1621, SB1628, SB1630, SB1631, SB1668, SB1672, SB1814, SB1821

Keywords: assisted living, health care, hyperbaric oxygen therapy, physician orders, informed consent, AHCCCS, remote work, state agency, employment, public health, housing, zoning, middle housing, urban development, duplexes, triplexes, fourplexes, townhomes, historic preservation, radiation protection

Transcript Highlights:

• disorder, or depression.
• or not depressed.
• or not depressed...
• or not depressed.
• or not depressed.

Summary: The Committee on Science and Technology met to hear a presentation from Ananya Lakaraju, a Hamilton High School junior, on her research into the biology of major depressive disorder. She described a project using saliva metabolomics and machine learning to identify potential biomarkers of depression from a UCSD dataset of 261 patient samples, explaining that the goal was to move beyond subjective screening toward more objective, biology-based diagnosis. She also discussed using multiple statistical methods and an ensemble AI model, along with SHAP and permutation importance, to identify top metabolites and related pathways, and said her work suggested some novel biomarkers and possible links to depression-related pathways. Lakaraju further explained a drug-discovery component of the project, in which she used pathway analysis and molecular docking software to identify a potential target protein and test candidate compounds, saying flupinazine showed the best binding energy in her simulations. She noted that the model achieved about 90% accuracy and a 97% AUC, and said she also built an app to collect mood and activity information to complement the biological data. Members asked questions about the metabolites, whether the findings were novel, how the saliva data were obtained, and how the app and future at-home testing might work. She said the biomarkers were computationally identified, the saliva data came from an online UCSD dataset rather than direct collection, and the app was intended to support more holistic diagnosis rather than replace clinicians. Committee members praised the presentation as impressive and timely, especially in light of the growing role of AI in medicine and the need for AI regulation. Lakaraju also spoke about her interest in coding and biology, her experience in robotics, and receiving the Governor’s Future Innovator of the Year Award. No formal votes or legislative actions were taken, and the meeting adjourned after the presentation and discussion.

Transcript Highlights:

• or not depressed.
• or not depressed... ...ultimately result in a single output of depressed or not depressed.
• Depression severity.
• or not depressed.
• or not depressed.

Keywords: 1182, all

Transcript Highlights:

• CDPH works with partners through programs like the Perinatal Equity Initiative and recently released

Summary: The hearing began with an overview of the California Health and Human Services Agency, which described its 2026-27 budget, major departments, and strategic priorities, including behavioral health, housing and human services integration, children and youth, and aging/disability services. The agency also explained a technical CalHHS/CalHires budget adjustment tied to HR1 compliance and eligibility system work. No LAO concerns were raised on that item. The committee then heard from the Office of Youth and Community Restoration on its budget, its SB 823 realignment report, and related issues. OYCR said county-based realignment has generally succeeded but outcomes and readiness vary widely, and it recommended more climate surveys, youth advisory councils, stronger behavioral management, better programming, improved transition planning, and integrated longitudinal data systems. Members pressed OYCR on “net widening,” county-by-county trends, and the gap between the detailed recommendations discussed in hearing and the more general recommendations in the public report. OYCR also described problems with federal Title II grant timing and a pending $14 million administrative funding adjustment, and discussed implementation of the juvenile justice realignment block grant formula. The Ombudsperson division separately requested two new positions due to rising complaints, site visits, and records-access disputes with counties; LAO noted the proposal would create ongoing General Fund costs. Several other departments presented budget change proposals. The State Council on Developmental Disabilities requested $730,000 General Fund ongoing to cover an interagency administrative support gap with DSS; LAO had no concerns. EMSA presented its department overview, said its AB 716 ambulance-rate report has been delayed after resources were reduced, and requested funding for disaster-response vehicle replacement, IT security assessment work, and additional HR/legal staff; members questioned delays, compliance, and the ongoing General Fund impact. The Department of Community Services and Development sought reappropriation of LIWIP funds and explained a new Proposition 4 process for continuing the farmworker housing component. The Department of Rehabilitation requested authority for $60 million in additional federal funds and 54 positions to meet growing vocational rehabilitation demand, with no General Fund impact. The Department of Child Support Services presented its budget and a supplemental report on full pass-through of child support collections. Members questioned why local agency funding was being restored despite declining caseloads, and staff explained that staffing costs have risen faster than caseload declines and that additional funding is needed to maintain service levels. The supplemental report estimated full pass-through would cost about $150 million General Fund annually, or about $80 million for a state-and-county portion, with $3 million to $5 million in automation costs. Finally, the Department of Public Health gave a broad overview of its $5.1 billion budget and its State of Public Health report, highlighting improved mortality and life expectancy, declining overdose deaths and STI rates, persistent racial and regional disparities, and increasing public health emergency demands. CDPH also warned that federal funding threats and policy changes are creating major uncertainty for state and local public health systems.

Transcript Highlights:

• CDPH works with partners through programs like the Perinatal Equity Initiative and recently released

Summary: The committee heard a series of budget and oversight presentations from CalHHS-related departments and agencies. CalHHS opened with a broad overview of its 2026-27 budget and priorities, including behavioral health, housing and human services integration, children and youth services, and aging/disability supports. OICR then presented its budget and its SB 823 realignment report on youth formerly committed to DJJ, saying county implementation varies widely but that the state has not seen evidence of net widening in the available data. OICR recommended climate surveys, youth advisory councils, stronger behavioral health and education programming in secure youth treatment facilities, better transitional planning, and improved longitudinal data systems. The agency also described a Title II federal grant transition problem, saying it cannot yet pay some subrecipients for prior work and is awaiting federal action on retroactive spending authority and an administrative funding adjustment. The Ombudsperson division requested two additional positions to address a growing complaint workload and access issues with counties over youth meetings, records, and grievance files; LAO raised no policy objection but noted the ongoing General Fund cost. The State Council on Developmental Disabilities requested $730,000 General Fund ongoing to cover the gap between federal limits on administrative overhead and the actual cost of an interagency agreement with the Department of Social Services. EMSA presented its department overview and several proposals, including a delayed AB 716 ambulance rate report, a $2.6 million request to replace aging disaster-response vehicles, a $250,000 security architecture assessment, and four positions plus ongoing General Fund for HR, enforcement, and legal workload. Members questioned the delay in the AB 716 report, the optics and timing of the vehicle replacement request, and whether EMSA was doing enough to prevent future staffing and enforcement problems. LAO repeatedly noted the ongoing General Fund implications of EMSA’s requests. The Department of Community Services and Development sought reappropriation of unspent Greenhouse Gas Reduction Fund money for the Low-Income Weatherization Program and described a Proposition 4-funded continuation of the farmworker housing component, which would require a new statewide administrator and program design process. The Department of Rehabilitation requested authority to draw an additional $60 million in federal funds annually and add 54 positions to meet sharply increased Vocational Rehabilitation caseloads; LAO had no concerns. Child Support Services proposed restoring a prior reduction to local child support agency funding and reported higher federal performance incentives, while also presenting a supplemental report on full pass-through of child support collections to CalWORKs families, estimating about $150 million annually for full pass-through or about $80 million for a state/county-only approach, plus automation costs. Members questioned why funding should rise when caseloads are declining, and whether the policy could be made cost-neutral. CDPH closed the hearing with an overview of its $5.1 billion budget and its state of public health report, highlighting record-low mortality and higher life expectancy, but also rising overdose deaths among ages 25-44, persistent maternal and infant mortality disparities, and the need for stable public health and emergency-response capacity; no votes were taken during the hearing.

Transcript Highlights:

• People with depression have a 40% higher risk of developing cardiac disease, hypertension, stroke, diabetes
• Kennedy, has been supportive of more than just psilocybin in use as a treatment for depression and other
• Psilocybin you can read dramatic dramatically reduce addiction and depression.
• For years I struggled with severe depression and a very unhealthy relationship with alcohol.
• I no longer live under the weight of severe depression.

Keywords: 1183, house

Transcript Highlights:

• </c> acute um you know acute depression acute um you know acute depression actually<01:24:05.040><c>
• depression who is actually acute depression who is determining<01:24:06.679><c> that</c><01:24:07.199
• </c><01:24:14.040><c> by</c> know I'm probably acute depression by know I'm probably acute depression
• </c> to a concern and we add aute depression to a concern and we add aute depression on<01:34:18.520>
• </c> streets because you're really depressed streets because you're really depressed yes<01:35:12.760

Keywords: 1191, senate, all

Transcript Highlights:

• intent is to facilitate quality improvement initiatives for Oklahoma birthing hospitals specific to perinatal

Bills: HB3329, HR1039, HR1040, HB3413, HB3414, HB3415, HB3416, HB3417, HB3418, HB3419, HB3420, HB3706, HB3711, HB4139, HB1268, HB3660, HJR1023, HB3298, HB3056, HJR1084, HB3934, HB3919, HB4118, HB4119, HB3791, HB4260, HB4178, HB4215, HB4324, HB3270, HB4352, HB4305, HB2955, HB3315, HB3066, HB1245, HB4125, HB3075, HB3129, HB3239, HB4153, HB3265, HB4491, SB680, HB4263, HB4268, HB1675, HB3885, HB2984, HB3697, HB2959, HB3671, HB3852, HB2933, HB3057, HB3802, HB4294, HB4285, HB3708, HB3979, HB3977, HB3986, HB3985, HB3588, HB3742, HB3845, HJR1070, HB3590, HB3595, HB3391, HB3183, HB3764, HB3765, HB1002, HB4434, HJR1086, HB4060, HB3881, HB3500, HB4408, HB3648, HB3127, HB3606

Keywords: long-term care, advisory board, sunset legislation, mental health, psychologists, University of Oklahoma, gymnastics, NCAA, congratulations, sports excellence, recognition, honor, athletics, Joseph Castiglione, leadership, education, sports management, HB3413, public finance, state budget

Transcript Highlights:

• Think early learning and other services like perinatal support.

Bills: SB6061, SB6234, SB6176, SB6335, SB6047, HB2235, HB2340, HB2464, HB2619, HB1376, HB1796, HB2091, HB2249, HB2254, HB2353, HB2431, HB2441, SB5808, SB5949, HB2124, HB1069, HB2104, HB2624, SB6061, SB6234, SB6176, SB6335, SB6047, HB2235, HB2464, HB2619, HB1376, HB1796, HB2091, HB2249, HB2353, HB2431, SB5808, SB5949, HB2124, HB2104, HB2624, HB2510, HB1347, HB1759, HB1983, HB2120, HB2264, HB2338, HB2385, HB2436, HB2495, HB2521, HB2604, HB2610, HB2675

Keywords: tourism, self-supported assessment, funding, statewide promotion, economic development, sewage, grinder pumps, residential buildings, regulation, construction, vehicle registration, enforcement, renewal, transportation, state law, state commission, infrastructure, traffic safety, responsibilities, state capital projects

Transcript Highlights:

• . depression. depression.
• And so, this is for treatment-resistant depression.
• Senator Fillingane. >> And so, this is for treatment-resistant depression.
• Um, treatment-resistant depression, substance use disorder, and other mental health indications.
• Um, treatment-resistant depression, substance use disorder, and other mental health indications.

Keywords: Drug Policy - Room 409, 26 February, 2026; 2:30 P.M., 925, all

Transcript Highlights:

• Unresponsive, you know, respiratory depression and so on.
• Higher doses mean more risk of respiratory depression.
• does not work on opioid receptors and cause respiratory depression like 7-OH.
• And it also helped me with depression.
• In my life, it's been meaningfully helpful for pain, anxiety, and depression.

Keywords: 987, senate, all

Summary: The hearing focused on kratom and 7-hydroxymitragynine (7-OH), with senators and witnesses debating public health risks, enforcement gaps, and whether California should regulate, restrict, or continue prohibiting these products. Committee members referenced prior bills, including AB 1088, and asked about the scientific evidence, overdose trends, testing limitations, and the effect of possible age limits or product distinctions between natural kratom leaf and concentrated 7-OH products. State and local public health officials said kratom and 7-OH are unlawful to manufacture or sell for consumption under current federal and state positions, and argued that the existing prohibition is the most protective approach. CDPH reported 169,000 past-year kratom users in California, 362 kratom-related overdose deaths from 2019 to 2023, and 15 deaths involving 7-OH on death certificates, while Los Angeles County officials described recent unexplained deaths in young adults linked to 7-OH and said local enforcement is resource-intensive and hampered by labeling and testing problems. Emergency and addiction medicine witnesses said 7-OH can cause opioid-like dependence, withdrawal, and overdose, sometimes requiring buprenorphine, methadone, or repeated naloxone, and warned that products sold in gas stations and smoke shops are misleadingly marketed as supplements or wellness products. Expert testimony also emphasized that 7-OH is much more potent than mitragynine, can be concentrated in products, and may pose respiratory depression risks similar to opioids. One researcher warned that scheduling kratom or 7-OH too broadly could discourage biomedical research and push use into the black market, while county health representatives said any future regulatory framework would need clear statewide standards and funding. In contrast, advocates for kratom and 7-OH argued that natural kratom leaf and concentrated 7-OH are different exposure classes, that natural kratom has long-standing use and should remain available with age-gating, labeling, testing, and packaging rules, and that bans would drive consumers to illicit markets and harm people using the products for pain or harm reduction.

Transcript Highlights:

• That animals demonstrate abstinence, withdrawal, respiratory depression at higher doses.
• Higher doses mean more risk of respiratory depression.
• does not work on opioid receptors and cause respiratory depression like 7-OH.
• And it also helped me with depression.
• In my life, it's been meaningfully helpful for pain, anxiety, and depression.

Summary: The committee held an informational hearing on kratom and 7-hydroxymitragynine (7-OH), focusing on public health risks, overdose deaths, and regulatory gaps in California. The chair opened by noting that FDA and CDPH consider kratom and 7-OH products unlawful, yet they remain widely sold in smoke shops, vape stores, gas stations, and convenience stores. Members referenced AB 1088, which would be considered later, and said the hearing was intended to clarify the science, medical perspective, and whether stronger safeguards are needed. The first panel featured a toxicology expert, state and local public health officials, an emergency/addiction physician, a medical examiner, and county health representatives. Witnesses from CDPH and Los Angeles County described rising deaths and enforcement actions, including statewide advisories, retailer letters, and product removals from manufacturers, wholesalers, and retailers. Medical testimony emphasized that 7-OH acts much more like an opioid than traditional kratom leaf, can cause dependence, withdrawal, and respiratory depression, and may require naloxone, buprenorphine, or methadone in overdose or withdrawal cases. Local officials said enforcement is difficult because packaging is inconsistent, testing capacity is limited, and counties lack resources and statewide infrastructure; they generally favored a centralized state framework if regulation is pursued. Committee members asked about testing, age restrictions, scheduling, and whether a distinction between kratom and 7-OH could be enforced. Witnesses said forensic labs can potentially test for 7-OH but validated assays are not routine, emergency departments cannot readily distinguish exposures, and local health departments do not have the lab capacity to verify product labels. Several officials warned that a ban or abrupt scheduling could push products into the black market and discourage research, while others argued that current prohibition and enforcement are the most protective approach because legalization or age-limited regulation could create confusion about legality and safety. The second panel included kratom and 7-OH advocates and industry representatives, who argued that natural kratom leaf and concentrated or synthetic 7-OH are different products and should be regulated differently. They supported age-gating, labeling, testing, and packaging rules for kratom leaf while opposing a ban on the botanical. They said 7-OH is used by many adults for pain relief or harm reduction, and that prohibition would drive consumers to illicit markets and worsen harm. Committee members pressed them on whether 7-OH is more potent than kratom, the availability of testing, and whether any safe dose is known. The hearing ended without a vote or formal action, with the chair noting the issue will continue to be considered in future legislation.

Transcript Highlights:

• It was a small carrier that did not cover postpartum depression screening.
• Uh, Senator Boyd, I think depression.
• Um and we when we did a depression.
• And um postpartum depression screening.
• The bill provides for depression screening, and it's a very straightforward bill.

Keywords: Medicaid - Room 216, 29 January, 2026; 2:00 PM, 925, all

Transcript Highlights:

• Like many other service members, I struggled with PTSD, anxiety, and depression.
• Like many other service members, I struggled with PTSD, anxiety, and depression.
• Suicide remains one of the most horrific complications of postpartum depression here in Hawaii.
• </c> complications of postpartum depression complications of postpartum depression um<00:54:13.319><c
• </c> with treatment resistant depression with treatment resistant depression anxiety<00:54:55.680><c>

Keywords: 912, senate, all

Summary: The Health and Human Services Committee heard testimony on several measures related to child welfare, health care access, overdose response, disability services, and waste management. For SB 710 on child welfare, the Department of Human Services, the Office of Wellness and Resilience, the Attorney General’s office, and multiple advocacy groups testified in support, with the Governor’s office noting support but deferring to the Attorney General on implementation because of separation-of-powers concerns. For SB 952 on child welfare services, DHS, the Governor’s office, and child- and trauma-informed care advocates supported the bill, saying it would help families access services, provide basic material support, and reduce strain on the child welfare system. SB 954 on a home health services rate study also drew support, including from DHS, the Hawaii Healthcare Association, and a public testifier who said the study would help ensure funds reach low-income, disabled, and kupuna recipients. SB 957 on overdose prevention received support from the Department of Health and the Attorney General, who said overdose prevention centers are evidence-based but raised federal-law concerns and recommended amendments; the Hawaii Health and Harm Reduction Center and others also testified in support. The committee then moved to the 1:00 regular calendar and heard SB 850 on disability health disparity, which was supported by the Executive Office on Aging, the Hawaii State Council on Developmental Disabilities, the Hawaii Disability Rights Center, self-advocates, and others. Testimony emphasized that a disparity study could improve workforce development, training, and services for people with disabilities. SB 838 on continuous glucose monitoring drew support from health agencies and advocates, with testimony stressing that monitors can be critical for some diabetes patients. SB 829 on health care was supported by the Department of Health and health care stakeholders, who said it would help rotating physicians serve neighbor islands without local hospital privileges and align with CMS rules. SB 446 on waste management drew mixed testimony: the Department of Health and several public entities provided comments, the County of Maui opposed, and environmental advocates urged stronger aquifer protections and limits on ash reuse. During decision making, the committee adopted recommendations to pass SB 298, SB 322, SB 299, SB 450, SB 451, SB 949, SB 710, SB 957, SB 69, and SD 952 with various amendments, including technical changes, blank appropriations, and defective dates. SB 323, SB 324, SB 712, SB 950, SB 954, and SB 959 were deferred, largely because companion House measures were moving or similar Senate measures had already passed. The chair also announced recesses to find quorum and noted that some bills from the earlier Monday calendar were being deferred to avoid duplication.

Transcript Highlights:

• </c> will use the term PTSD and depression. will use the term PTSD and depression.
• And all you need to really depression.
• </c> So, um, addiction, PTSD, and depression So, um, addiction, PTSD, and depression all<00:32:13.760
• ><c> as</c><00:32:30.559><c> damaging</c> don't think of depression as damaging don't think of depression
• </c> category, not in the PTSD or depression category, not in the PTSD or depression category. category

Keywords: 958, all

Summary: The committee first reviewed preferred administrative regulations and, hearing no concerns, considered them reviewed. It then took up House Bill 388, described as a Casper cleanup bill. The sponsor said it would exempt charitable health care providers from e-prescribing requirements, allow Casper data sharing with certain federal entities, update references to hydrocodone’s schedule status, clean up drafting errors, and clarify practitioner registration with Casper. The bill passed 9-0 and was then approved for consent. Next, House Bill 134 was presented as a follow-up to a prior study on shortages of sexual assault nurse examiners and SANE-ready hospitals. The sponsor and a representative from the Kentucky Association of Sexual Assault Programs said the bill would create a statewide SANE coordinator. The committee adopted a substitute, then passed the bill unanimously and sent it to consent. Senate Bill 147 was then heard as an administrative update to vital records, modernizing certified-copy requests, adjusting fees, and requiring the Cabinet for Health and Family Services to send the annual death report to the State Board of Elections by July 1 each year. It passed unanimously and was also moved to consent. House Bill 280, a Kentucky Board of Nursing cleanup bill, would let the board investigate out-of-state nurses applying for Kentucky licenses, clarify licensing language, and update school rescue medication provisions, including inhalers, nebulizers, glucagon, Solu-Cortef, and nasal epinephrine. A committee substitute narrowed the bill to glucagon updates, and one senator asked whether the bill also covered child care centers; the sponsor said it addressed school medications only but was open to further discussion. The bill passed 10-0 and was reported favorably. Finally, Senate Bill 77 drew extended testimony. The sponsor and supporters argued that ibogaine research and treatment could help address addiction, PTSD, and depression, citing studies, personal recovery stories, and a proposed public-private partnership funded through opioid settlement money. The committee substitute removed the bill’s appropriation request and emergency clause, and members asked questions about whether PTSD is an addiction, whether smoking was included, whether the bill was authorizing research rather than funding, and how the treatment works. The sponsor said the substitute was only creating a structure for research, not appropriating money, and supporters described ibogaine as a one-time, medically supervised treatment. The transcript cuts off before a final vote on Senate Bill 77 is shown.

Transcript Highlights:

• Um, mandatory depression screenings require that each inmate who is pregnant or has given birth in the
• preceding year be screened for depression at specific intervals.
• HB 1826 will help address this by requiring regular depression screenings for incarcerated women during
• Maternal depression can disrupt infant development and bonding.
• Approximately 1/3 of the women's jail prison population suffers from some form of depression.

Transcript Highlights:

• Higher doses mean more risk of respiratory depression.
• does not work on opioid receptors and cause respiratory depression like 7-OH.
• And it also helped me with depression.
• And it also helped me with depression.
• In my life, it's been meaningfully helpful for pain, anxiety, and depression.

Summary: The committee held an informational hearing on kratom and 7-hydroxymitragynine (7-OH), focusing on public health risks, overdose deaths, and regulatory gaps in California. The chair opened by noting that FDA and CDPH consider kratom and 7-OH products unlawful for consumption, yet they remain widely sold in smoke shops, vape stores, gas stations, and convenience stores. The hearing was framed as part of ongoing legislative work, including a future review of AB 1088, and members emphasized the need to weigh potential benefits against risks and consider whether stronger safeguards are needed. Expert testimony from a toxicology professor and several public health and medical officials described kratom as a plant with multiple alkaloids, with 7-OH identified as the more potent opioid-like compound associated with tolerance, dependence, withdrawal, and respiratory depression. CDPH reported 362 kratom-related overdose deaths in California from 2019 to 2023 and 15 deaths involving 7-OH, while Los Angeles County officials described unexplained deaths in young adults that led them to expand toxicology testing and identify 7-OH as a common factor. County and state public health representatives said they have issued advisories, contacted retailers, removed products from shelves, and taken enforcement actions, but they stressed that local enforcement is patchy, under-resourced, and limited by unclear jurisdiction and lack of testing capacity. Medical witnesses said patients are presenting with 7-OH dependence and withdrawal in ways similar to fentanyl-related cases, sometimes requiring buprenorphine, methadone, or repeated naloxone. They argued that unregulated retail sales and misleading marketing make the products especially risky, and that a statewide framework would be more effective than a patchwork of local ordinances. Some officials said the safest current policy is to keep kratom and 7-OH unlawful for consumption, while others said any new regulation would need resources, packaging rules, and clearer authority for enforcement. Industry and consumer advocates urged the committee to distinguish natural kratom leaf from concentrated or synthetic 7-OH products. They argued that kratom leaf has long-standing use, that 7-OH should be targeted rather than the whole plant, and that regulation should focus on age limits, labeling, testing, serving-size caps, and restrictions on adulterated products rather than prohibition. Several speakers warned that bans could push demand to the black market and reduce access for people using the products for pain relief or harm reduction, while critics of the industry said the products are being marketed deceptively and that more comprehensive regulation is needed.

Transcript Highlights:

• Nearly half of patients with depression actually never seek care.
• Nearly half of patients with depression actually never seek care.
• ,</c><00:04:44.080><c> anxiety</c> can be as simple as depression, anxiety can be as simple as depression
• </c> Nearly half of patients with depression Nearly half of patients with depression actually<00:04:52.720
• So self-dagnosed anxiety or depression.

Keywords: 00:00 - Call to Order/Roll Call 02:05 - Discussion of 26RS HB 178 14:05 - Roll Call Vote on 26RS HB 178 15:05 - Discussion of 26RS HB 280 20:00 - Roll Call Vote on 26RS HB 280 22:00 - Discussion of 26RS HJR 24 24:30 - Roll Call Vote on 26RS HJR 24 26:00 - Adjournment, 958, all

Transcript Highlights:

• According to the Anxiety and Depression Society of America, one in 10 experience depression.
• According to the Anxiety and Depression Society of America, one in 10 experience depression.
• According to the Anxiety and Depression Society of America, one in 10 experience depression.
• Depression is real.
• Depression is real.

Keywords: U.S. House of Representatives Floor Proceedings on Monday, June 9, 2025, 1012, house, all

Transcript Highlights:

• These are people who depression.
• depression depression uh<01:24:14.000><c> PTSD</c><01:24:14.880><c> be</c><01:24:15.040><c> it</c><01
• so major depressive resistant depression so major depressive disorder<01:32:44.159><c> is</c><01:32:
• </c><01:32:54.560><c> TRD</c> treatment resistant depression TRD treatment resistant depression TRD um
• </c> depression symptoms. depression symptoms.

Keywords: 1191, senate, all